Literature DB >> 11595430

Otilonium bromide enhances sensory thresholds of volume and pressure in patients with irritable bowel syndrome.

J Czimmer1, G Süto, A Király, G Mózsik.   

Abstract

UNLABELLED: Visceral hyperalgesia has been suggested to play a role in the development of symptoms presented by irritable bowel syndrome patients. Otilonium bromide was developed to block smooth muscle Ca release to control cramping pain of these patients. AIMS: to determine whether otilonium bromide can influence sensory thresholds of patients suffering from irritable bowel syndrome.
METHODS: 15 patients with Rome-II positive IBS were tested by Synectics Visceral Stimulator Barostat using rapid phasic distension (870 ml/min). The sensory threshold for first sensation, stool, pain and maximum tolerable volume and pressure were measured. All of the parameters were tested before and 1 week after the initiation of otilonium bromide (Spasmomen, Berlin Chemie, 3x40 mg) therapy.
RESULTS: The perceptual thresholds for first sensation, stool, pain and maximum tolerable distention were, 8.8+/-1.7 Hgmm, 19.2+/-2.1 Hgmm, 26.3+/-2.8 Hgmm, 28.7+/-2.8 Hgmm for pressure, 90+/-21 ml, 145+/-28 ml, 208+/-25 ml, 213+/-28 ml for volume, before treatment, respectively. Otilonium bromide treatment did not influence the thresholds for first sensation and stool, 7.4+/-1.4 Hgmm, 20.7+/-4.6 Hgmm and 83+/-21 ml, 178+/-35.8 ml, respectively. The pressure threshold of pain was significantly higher 1 week after treatment (26.3+/-2.8 Hgmm vs. 29.1+/-5.5 Hgmm, P<0.05), but the volume threshold of this sensation remained unchanged (208+/-25 ml vs. 234+/-39 ml, not significant). The pressure (28.7+/-2.8 Hgmm vs. 38.1+/-3.4 Hgmm, P<0.05) and volume (213+/-28 ml vs. 278+/-27 ml, P<0.05) thresholds for maximum tolerable volume were increased by 7 days otilonium bromide treatment.
CONCLUSION: These data suggest that otilonium bromide enhances sensory thresholds to recto-sigmoideal distention.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11595430     DOI: 10.1016/s0928-4257(01)00020-1

Source DB:  PubMed          Journal:  J Physiol Paris        ISSN: 0928-4257


  11 in total

1.  Changes in nitrergic and tachykininergic pathways in rat proximal colon in response to chronic treatment with otilonium bromide.

Authors:  G Cipriani; S J Gibbons; S A Saravanaperumal; J Malysz; L Sha; J H Szurszewski; D R Linden; S Evangelista; M S Faussone-Pellegrini; M G Vannucchi; G Farrugia
Journal:  Neurogastroenterol Motil       Date:  2015-04-30       Impact factor: 3.598

Review 2.  Irritable bowel syndrome.

Authors:  Antonella Spinelli
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

3.  Pooled analysis of brain activity in irritable bowel syndrome and controls during rectal balloon distension.

Authors:  J Sheehan; A Gaman; M Vangel; B Kuo
Journal:  Neurogastroenterol Motil       Date:  2010-11-30       Impact factor: 3.598

Review 4.  Colonic smooth muscle cells and colonic motility patterns as a target for irritable bowel syndrome therapy: mechanisms of action of otilonium bromide.

Authors:  Jakub Rychter; Francisco Espín; Diana Gallego; Patri Vergara; Marcel Jiménez; Pere Clavé
Journal:  Therap Adv Gastroenterol       Date:  2014-07       Impact factor: 4.409

Review 5.  Role of antispasmodics in the treatment of irritable bowel syndrome.

Authors:  Anita Annaházi; Richárd Róka; András Rosztóczy; Tibor Wittmann
Journal:  World J Gastroenterol       Date:  2014-05-28       Impact factor: 5.742

Review 6.  Pharmacological agents currently in clinical trials for disorders in neurogastroenterology.

Authors:  Michael Camilleri
Journal:  J Clin Invest       Date:  2013-10-01       Impact factor: 14.808

Review 7.  Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome.

Authors:  Lisa Ruepert; A Otto Quartero; Niek J de Wit; Geert J van der Heijden; Gregory Rubin; Jean Wm Muris
Journal:  Cochrane Database Syst Rev       Date:  2011-08-10

8.  The evaluation of otilonium bromide treatment in asian patients with irritable bowel syndrome.

Authors:  Full-Young Chang; Ching-Liang Lu; Jiing-Chyuan Luo; Tseng-Shing Chen; Mei-Jung Chen; Hsiu-Ju Chang
Journal:  J Neurogastroenterol Motil       Date:  2011-10-31       Impact factor: 4.924

9.  Efficacy of otilonium bromide in irritable bowel syndrome: a pooled analysis.

Authors:  Pere Clavé; Jan Tack
Journal:  Therap Adv Gastroenterol       Date:  2017-01-16       Impact factor: 4.409

Review 10.  Long-term efficacy and safety of otilonium bromide in the management of irritable bowel syndrome: a literature review.

Authors:  John K Triantafillidis; George Malgarinos
Journal:  Clin Exp Gastroenterol       Date:  2014-04-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.